Theravance Biopharma (TBPH) Accounts Payables (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Accounts Payables data on file, last reported at $1.1 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.1 million, down 54.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 54.32% YoY), and the FY2025 annual result was $2.6 million, up 14.54% from the prior year.
• Accounts Payables declined to $1.1 million in Q1 2026 per TBPH's latest filing, from $2.6 million in the prior quarter.
• Over five years, Accounts Payables peaked at $5.3 million in Q3 2022 and troughed at $1.1 million in Q1 2026.
• A 5-year average of $2.2 million and a median of $1.7 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables tumbled 77.9% in 2022, then surged 76.36% in 2023.
• A 5-year view of Accounts Payables shows it stood at $1.6 million in 2022, then slipped by 1.93% to $1.5 million in 2023, then soared by 47.11% to $2.2 million in 2024, then advanced by 14.54% to $2.6 million in 2025, then sank by 57.17% to $1.1 million in 2026.
• Business Quant data shows TBPH's Accounts Payables at $1.1 million in Q1 2026, $2.6 million in Q4 2025, and $2.2 million in Q3 2025.